AstraZeneca

Johnson & Johnson will invest $2 billion over 10 years to build a 160,000+ square foot manufacturing facility at Fujifilm Biotechnologies' new Holly Springs, North Carolina site.

Former FDA Commissioner Dr. Stephen Hahn has been appointed CEO of Nucleus RadioPharma, a contract development and manufacturing organization specializing in radiopharmaceuticals for targeted cancer therapy.

AlzeCure Pharma has appointed Cecilia Wadell, MScPharm, Ph.D., as Head of Development to lead the clinical development organization effective August 20, 2025.

The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies.

Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.

AstraZeneca's FluMist Home is now available for home delivery in 34 US states, marking the first time Americans can self-administer a flu vaccine at home.

FibroGen has reached agreement with the FDA on key design elements for a pivotal Phase 3 trial of roxadustat in lower-risk myelodysplastic syndrome patients with high transfusion burden.

Alexion, AstraZeneca's Rare Disease division, has reached a Letter of Intent with Canada's pan-Canadian Pharmaceutical Alliance for public reimbursement of Ultomiris (ravulizumab) for NMOSD and generalized myasthenia gravis patients.

SOPHiA GENETICS and AstraZeneca announced a multi-year collaboration expansion to leverage multimodal AI Factories for generating evidence on breast cancer therapy efficacy and real-world impact.

Symbiosis Pharmaceutical Services, a global contract manufacturing organization, has successfully completed its 1,000th sterile drug product batch since its founding in 2011.